1
Clinical Trials associated with Human cord derived MSC cells (Hamilton Biotech)人脐带间充质干细胞注射液治疗膝关节骨性关节炎的单中心、开放、剂量递增 I 期临床试验
[Translation] A single-center, open-label, dose-escalation phase I clinical trial of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis
主要目的:评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的安全性和耐受性,为 II 期临床试验推荐合适的细胞治疗剂量(RP2D)。次要目的:评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的初步有效性。评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的免疫原性。
[Translation] Primary objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis, and to recommend an appropriate cell therapy dose (RP2D) for Phase II clinical trials. Secondary objective: To evaluate the preliminary efficacy of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. To evaluate the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis.
100 Clinical Results associated with Human cord derived MSC cells (Hamilton Biotech)
100 Translational Medicine associated with Human cord derived MSC cells (Hamilton Biotech)
100 Patents (Medical) associated with Human cord derived MSC cells (Hamilton Biotech)
100 Deals associated with Human cord derived MSC cells (Hamilton Biotech)